Business ❯ Biotechnology ❯ Pharmaceuticals

Clinical Trials

Drug Development Duchenne Muscular Dystrophy Nanobody Technology Gene Therapy Antidepressants mRNA Technology Influenza Treatments TIL Cell Therapies CAR T Therapy Stock Market Market Performance Regulatory Approval Regulatory Affairs CNS Cancers Immunotherapy Antengene Corporation Deramiocel

Capricor Hit with Multiple Investor Lawsuits After FDA Questions Unagreed Trial Analysis

Investor groups are racing to seek lead‑plaintiff status following the FDA’s decision to extend its review of deramiocel to November 22, 2026.

AbCellera’s Menopause Antibody Hits Phase 2 Goals

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

Legend Biotech Q1 Sales Jump on CARVYKTI Growth Despite Expansion-Related Margin Hit

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Law Firms Press MoonLake Class Action Over SLK Claims as Lead‑Plaintiff Deadline Nears

Cidara Gains on JP Morgan Coverage Initiation as ESWI Presentation Nears